Skip to main content

Advertisement

SpringerLink
Log in

68Ga-somatostatin analogues PET and 18F-DOPA PET in medullary thyroid carcinoma

  • Editorial Commentary
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Fialkowski EA, Moley JF. Current approaches to medullary thyroid carcinoma, sporadic and familial. J Surg Oncol 2006;94:737–47.

    Article  CAS  PubMed  Google Scholar 

  2. Lairmore TC, Wells SA Jr. Medullary carcinoma of the thyroid: current diagnosis and management. Sem Surg Oncol 1991;7:92–9.

    Article  CAS  Google Scholar 

  3. Dralle H. Lymph node dissection and medullary thyroid carcinoma. Br J Surg 2002;89:1073–5.

    Article  CAS  PubMed  Google Scholar 

  4. Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d’étude des tumeurs à calcitonine. Clin Endocrinol 1998;48:265–73.

    Article  CAS  Google Scholar 

  5. Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 2001;28:1671–6.

    Article  CAS  PubMed  Google Scholar 

  6. Adams S, Baum R, Rink T, Schumm-Dräger PM, Usadel KH, Hör G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumors. Eur J Nucl Med 1998;25:79–83.

    Article  CAS  PubMed  Google Scholar 

  7. Eidelberg D, Moeller JR, Dhawan V, Sidtis JJ, Ginos JZ, Strother SC, et al. The metabolic anatomy of Parkinson’s disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. Mov Disord 1990;5(3):203–13.

    Article  CAS  PubMed  Google Scholar 

  8. Ribeiro MJ, Boddaert N, Bellanné-Chantelot C, Bourgeois S, Valayannopoulos V, Delzescaux T, et al. The added value of [18F]fluoro-L-DOPA PET in the diagnosis of hyperinsulinism of infancy: a retrospective study involving 49 children. Eur J Nucl Med Mol Imaging 2007;34(12):2120–8.

    Article  CAS  PubMed  Google Scholar 

  9. Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 2001;28:64–71.

    Article  CAS  PubMed  Google Scholar 

  10. Kauhanen S, Seppänen M, Ovaska J, Minn H, Bergman J, Korsoff P, et al. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors. Endocr Relat Cancer 2009;16(1):255–65.

    Article  CAS  PubMed  Google Scholar 

  11. Beuthien-Baumann B, Strumpf A, Zessin J, Bredow J, Kotzerke J. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2007;34:1604–09.

    Article  CAS  PubMed  Google Scholar 

  12. Beheshti M, Pöcher S, Vali R, Waldenberger P, Broinger G, Nader M et al. (2009) The value of (18)F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with (18)F-FDG PET-CT. Eur Radiol 2009;19:1425–34.

    Article  PubMed  Google Scholar 

  13. Pestourie C, Thézé B, Kuhnast B, Le Helleix S, Gombert K, Dollé F et al. PET imaging of medullary thyroid carcinoma in MEN-2A transgenic mice using 6-[18F]F-L-DOPA. Eur J Nucl Med Mol Imaging 2009; doi:10.1007/s00259-009-1208-8.

  14. Ciampi R, Vivaldi A, Romei C, Del Guerra A, Salvadori P, Cosci B, et al. Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors. Mol Cell Endocrinol 2008;291(1–2):57–62.

    Article  CAS  PubMed  Google Scholar 

  15. Schonberger J, Ruschoff J, Grimm D, Marienhagen J, Rummele P, Meyringer R, et al. Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis: an immunohistochemical study. Thyroid 2002;12:747–54.

    Article  PubMed  Google Scholar 

  16. Stokkel MP, Duchateau CS, Dragoiescu C. The value of FDG-PET in the follow-up of differentiated thyroid cancer: a review of the literature. Q J Nucl Med Mol Imaging 2006;50:78–87.

    CAS  PubMed  Google Scholar 

  17. Khan N, Oriuchi N, Higuchi T, Endo K. Review of fluorine-18–2-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas. Cancer Control 2005;12:254–60.

    PubMed  Google Scholar 

  18. Conti PS, Durski JM, Bacqai F, Grafton ST, Singer PA. Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid 1999;9:797–804.

    Article  CAS  PubMed  Google Scholar 

  19. Faggiano A, Grimaldi F, Pezzullo L, Chiofalo MG, Caracò C, Mozzillo N, et al. Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer. Endocr Relat Cancer 2009;16(1):225–31.

    Article  CAS  PubMed  Google Scholar 

  20. Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007;34(7):982–93.

    Article  CAS  PubMed  Google Scholar 

  21. Pettinato C, Sarnelli A, Di Donna M, Civollani S, Nanni C, Montini G, et al. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2008;35(1):72–9.

    Article  CAS  PubMed  Google Scholar 

  22. Reubi JC, Chayvialle JA, Franc B, Cohen R, Calmettes C, Modigliani E. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest 1991;64(4):567–73.

    CAS  PubMed  Google Scholar 

  23. Koukouraki S, Strauss LG, Georgoulias V, Schuhmacher J, Haberkorn U, Karkavitsas N, et al. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006;33(4):460–6.

    Article  CAS  PubMed  Google Scholar 

  24. Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging 2008;35(8):1431–8.

    Article  CAS  PubMed  Google Scholar 

  25. Haug A, Auernhammer CJ, Wängler B, Tiling R, Schmidt G, Göke B, et al. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2009;36(5):765–70.

    Article  CAS  PubMed  Google Scholar 

  26. Conry BG, Papathanasiou ND, Prakash V, Kayani I, Caplin M, Mahmood S, et al. Comparison of 68Ga-DOTATATE and 18F-fruorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2009; doi:10.1007/s00259-009-1204-z.

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, PET Centre, Policlinico S. Orsola-Malpighi, Bologna, Italy

    Valentina Ambrosini & Stefano Fanti

  2. Department of Nuclear Medicine, PET Centre, S. Maria della Misericordia Hospital, Rovigo, Italy

    Maria Cristina Marzola & Domenico Rubello

Authors
  1. Valentina Ambrosini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Cristina Marzola
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Domenico Rubello
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stefano Fanti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Domenico Rubello.

Additional information

This Editorial Commentary refers to the article doi:10.1007/s00259-009-1204-z and doi:10.1007/s00259-009-1208-8.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ambrosini, V., Marzola, M.C., Rubello, D. et al. 68Ga-somatostatin analogues PET and 18F-DOPA PET in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 37, 46–48 (2010). https://doi.org/10.1007/s00259-009-1247-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-009-1247-1

Search

Navigation